Sovaldi patent challenger Natco eyes big price drop
This article was originally published in Scrip
Executive Summary
Sovaldi (sofosbuvir) patent challenger Natco Pharma believes that a generic version of Gilead Sciences' hepatitis C drug could be priced at a fraction of that of the innovator product on the Indian market.